Verseon Corporation (“Verseon” or the “Company”)
Additional Listing and Total Voting Rights
Verseon, a technology-based pharmaceutical company, announces that application has been made for 24,006 new Common Shares of par value $0.001 each (the “Common Shares”) to be admitted to trading on AIM pursuant to the exercise of warrants issued and restricted stock grants (the "Exercise").
Of the 24,006 Common Shares issued, 4,322 Common Shares have been issued to Dr. Thomas Hecht, Non-Executive Chairman of the Company, in relation to payment of his Director’s fees in the form of restricted stock totalling 17,291 Common Shares vesting quarterly in equal proportions over a one year period. Following Admission, Dr. Hecht will hold 8,644 Common Shares, representing 0.006% of the Company’s issued share capital.
The 24,006 new Common Shares issued pursuant to the Exercise will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on 30 October 2015 ("Admission").
Total Voting Rights
Following Admission, the issued share capital of the Company will consist of 150,878,815 Common Shares. The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 150,878,815. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
|Verseon Corporation||+1 (510) 225 9000|
|Arthur Shmurun / Amy Thai|
|Cenkos Securities (NOMAD and Broker)||+44 (0) 20 7397 8900|
|Mark Connelly / Christopher Golden|
|Abchurch Communications Ltd (PR Advisers)||+44 (0) 20 7398 7719|
|Jamie Hooper / Viktoria Langley / Alex Shaw|